Can-Fite BioPharma announced that its Phase 2a study results for Namodenoson in advanced pancreatic cancer have been accepted for presentation at the ESMO Congress 2026. This acceptance provides scientific validation for their drug candidate and offers an opportunity to showcase positive data to the global oncology community, potentially boosting investor confidence.
Can-Fite BioPharma (CANF) announced that an abstract detailing positive results from its Phase 2a study of Namodenoson in advanced pancreatic cancer has been accepted for poster presentation at the prestigious European Society for Medical Oncology (ESMO) Congress in 2026. This is a significant development as acceptance at ESMO provides scientific recognition and a platform to present encouraging survival outcomes and durable disease stabilization data to a global audience of oncologists and potential partners. For CANF, this is a positive long-term catalyst, as it validates their research and could attract further investment or collaboration for the planned Phase 2b study. While the presentation is in 2026, the immediate acceptance news can generate short-term positive sentiment for the stock, as it de-risks the program to some extent and highlights the potential of Namodenoson in a difficult-to-treat cancer.